Brief: Lonza Posts Strong CDMO Performance In Q1 2025

Lonza AG

09/05/2025 05:37

May 9 (Reuters) - LONZA GROUP AG LONN.S:

STRONG CDMO^1 PERFORMANCE IN Q1 2025, IN LINE WITH EXPECTATIONS FOR FY 2025

CDMO OUTLOOK 2025 CONFIRMED WITH CER^2 SALES GROWTH APPROACHING 20% AND CORE EBITDA MARGIN APPROACHING 30%

CHI CONFIRMS ITS OUTLOOK TO RETURN TO LOW-TO-MID-SINGLE-DIGIT CER SALES GROWTH IN 2025 WITH AN IMPROVING CORE EBITDA MARGIN IN MID-TWENTIES

MID-TERM OUTLOOK CONFIRMED

Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS

DOES NOT ANTICIPATE A MATERIAL FINANCIAL IMPACT FROM POTENTIAL TARIFFS

LONZA NOW ANTICIPATES START OF OPERATIONS AT ITS NEW COMMERCIAL-SCALE ASEPTIC DRUG PRODUCT FACILITY IN STEIN (CH) IN 2027

IN Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS

CUSTOMER INTEREST IN VACAVILLE IS STRONG, WITH A THIRD LONG-TERM CUSTOMER CONTRACT SECURED AND A NUMBER OF CONTRACT NEGOTIATIONS ONGOING

MAKING GOOD PROGRESS WITH PREPARATIONS FOR EXIT OF CHI BUSINESS

CHI BUSINESS: CURRENTLY PLANNING NECESSARY CARVE-OUT MEASURES

Source text: ID:nEQXP8L5a

Further company coverage: LONN.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))